Juntunen, Pekka
Salmela, Petri
Pakkasela, Johanna
Karjalainen, Jussi
Lehtimäki, Lauri
Funding for this research was provided by:
Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital
Hengityssairauksien Tutkimussäätiö
Tampereen Tuberkuloosisäätiö
Tays tukisäätiö
Tampere University
Article History
Received: 25 April 2023
Accepted: 19 January 2024
First Online: 31 January 2024
Declarations
:
: The study protocol was approved by the Ethics Committee of Tampere University Hospital (approval number R15186). Written informed consent to participate was obtained from the participants.
: Not applicable as information in the manuscript cannot lead to identification of a study participant.
: P.J. reports no conflicts of interest. P.S. reports fees for lectures and advisory board meetings from GSK, Boehringer Ingelheim and Astra Zeneca. J.P. reports fees for lectures from GSK. J.K. and L.L. report fees for lectures and advisory board meetings from ALK, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi and Orion Pharma.